|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.14 USD | +0.47% |
|
+14.16% | +30.44% |
Company Valuation: Arcus Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,843 | 1,497 | 1,430 | 1,363 | 2,948 | 3,899 | - | - |
| Change | - | -47.33% | -4.52% | -4.7% | 116.38% | 32.24% | - | - |
| Enterprise Value (EV) 1 | 2,344 | 488.4 | 670.7 | 384.6 | 2,066 | 3,278 | 3,640 | 3,519 |
| Change | - | -79.16% | 37.34% | -42.66% | 437.29% | 58.61% | 11.04% | -3.31% |
| P/E | 57x | -5.57x | -4.6x | -4.74x | -7.24x | -8.44x | -9.19x | -10.7x |
| PBR | - | 2.29x | 3.12x | 2.83x | 4.73x | 20.5x | -18.9x | 20.4x |
| PEG | - | 0x | -0.4x | 0.2x | -1.52x | -0.7x | 1.12x | 0.7x |
| Capitalization / Revenue | 7.43x | 13.4x | 12.2x | 5.28x | 11.9x | 45.8x | 41.9x | 23.2x |
| EV / Revenue | 6.12x | 4.36x | 5.73x | 1.49x | 8.37x | 38.5x | 39.1x | 21x |
| EV / EBITDA | 40.3x | -1.78x | -2.02x | -1.28x | -5.5x | -6.94x | -8.01x | -12.3x |
| EV / EBIT | 43.2x | -1.74x | -1.97x | -1.17x | -5.35x | -6.65x | -7.53x | -7.59x |
| EV / FCF | -8.3x | 1.13x | - | -2.19x | -4.27x | -12.7x | -10.9x | -18.5x |
| FCF Yield | -12% | 88.5% | - | -45.8% | -23.4% | -7.89% | -9.16% | -5.41% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.71 | -3.71 | -4.15 | -3.14 | -3.29 | -3.675 | -3.372 | -2.885 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 382.9 | 112 | 117 | 258 | 247 | 85.06 | 93.06 | 167.8 |
| EBITDA 1 | 58.09 | -274 | -332 | -300 | -376 | -472.1 | -454.5 | -285.6 |
| EBIT 1 | 54.25 | -280 | -340 | -330 | -386 | -492.6 | -483.2 | -463.6 |
| Net income 1 | 52.83 | -267 | -307 | -283 | -353 | -456.4 | -430.5 | -394.5 |
| Net Debt 1 | -499.3 | -1,009 | -759 | -978 | -882 | -621.3 | -259.3 | -379.9 |
| Reference price 2 | 40.47 | 20.68 | 19.10 | 14.89 | 23.83 | 31.00 | 31.00 | 31.00 |
| Nbr of stocks (in thousands) | 70,249 | 72,408 | 74,856 | 91,512 | 123,729 | 125,773 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 2/21/24 | 2/25/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.44x | 38.53x | -6.94x | -.--% | 3.9B | |
| 32.21x | 5.68x | 17.59x | 1.02% | 46.2B | |
| -22.9x | 343.72x | -21.86x | -.--% | 38.71B | |
| 23.26x | 2.64x | 11.39x | -.--% | 31.9B | |
| 41.76x | 4.18x | 26.75x | -.--% | 31.12B | |
| 27.93x | 7.24x | 18.62x | 0.45% | 23.77B | |
| 30.92x | 5x | 22.8x | -.--% | 15.05B | |
| 23.95x | 2.04x | 8.96x | 1.12% | 13.74B | |
| -22.52x | 14.77x | -22.09x | -.--% | 13.42B | |
| Average | 14.02x | 47.09x | 6.14x | 0.29% | 24.2B | |
| Weighted average by Cap. | 17.29x | 66.14x | 8.02x | 0.34% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RCUS Stock
- Valuation Arcus Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
